Boston Immune Technologies and Therapeutics (BITT), a developer of TNFSR antagonist antibodies, has partnered with McQuade Center for Strategic Research and Development (MSRD) to advance the preclinical development of BITT’s CD40 antagonist. MSRD will fund non-human primate studies, granting them exclusive negotiation rights for an acquisition, license, or collaboration agreement for the asset.
Additionally, BITT has received a $4 million grant from the National Institute of Health/National Cancer Institute (NIH/NCI) for the ongoing Phase I clinical trial of their TNFR2 antagonist, BIR2101. This grant supports BITT’s TNFR2 oncology program and validates the potential of TNFR2 as a therapeutic target.
BITT’s DOMab platform enables the development of antagonist antibodies targeting TNF superfamily receptors. BIR2101, a monoclonal antibody targeting TNFR2, is currently in clinical trials for cancer treatment. BITT also has other antibodies targeting TNF superfamily receptors for inflammation, oncology, and infectious diseases in development.
BITT is headquartered in Boston, Massachusetts, and is committed to advancing novel therapies for various diseases. Their collaboration with MSRD and the NIH/NCI grant demonstrates the recognition and potential of BITT’s research in immunology and cancer treatment.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
